Therapeutic Response

EGFR positive and Wild type KRAS status confers therapeutic sensitivity to Cetuximab in patients with Colorectal Adenocarcinoma.

Statements

Source and description
Erbitux (cetuximab) [package insert]. FDA. The U.S. Food and Drug Administration granted approval to cetuximab for the treatment of patients with K-Ras wild-type, EGFR-expressing metastatic colorectal cancer, as determined by an FDA-approved test, who have failed oxaliplatin- and irinotecan-based chemotherapy or who are intolerant to irinotecan.